Evidence map›Paper›PMID 28345551›Full record

ArticleChinese medical journal2017

Biliverdin Protects the Isolated Rat Lungs from Ischemia-reperfusion Injury via Antioxidative, Anti-inflammatory and Anti-apoptotic Effects.

Wen-Fang Tian, Ping Weng, Qiong Sheng, Jun-Liang Chen, Peng Zhang, Ji-Ru Zhang, Bin Du, Min-Chen Wu, Qing-Feng Pang, Jian-Jun Chu

Open access · goldAbstract read
In one paragraph

Article in Chinese medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Inhibition of gp130 alleviates LPS-induced lung injury by attenuating apoptosis and inflammation through JAK1/STAT3 signaling pathway.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Wen-Fang TianDepartment of Pathophysiology, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, China.
Ping WengDepartment of Pathophysiology, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, China.
Qiong ShengDepartment of Pathophysiology, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, China.
Jun-Liang ChenDepartment of Pathophysiology, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, China.
Peng ZhangDepartment of Pathophysiology, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, China.
Ji-Ru ZhangDepartment of Anesthesia, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214122, China.
Bin DuDepartment of Pathophysiology, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, China.
Min-Chen WuDepartment of Pathophysiology, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, China.
Qing-Feng PangDepartment of Pathophysiology, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, China.
Jian-Jun ChuDepartment of Anesthesia, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214122, China.
Jiangnan University · CNWuxi Fourth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiliverdin (BV) has a protective role against ischemia-reperfusion injury (IRI). However, the protective role and potential mechanisms of BV on lung IRI (LIRI) remain to be elucidated. Thus, we aimed to investigate the protective role and potential mechanisms of BV on LIRI.

methodsLungs were isolated from Sprague-Dawley rats to establish an ex vivo LIRI model. After an initial 15 min stabilization period, the isolated lungs were subjected to ischemia for 60 min, followed by 90 min of reperfusion with or without BV treatment.

resultsLungs in the I/R group exhibited significant decrease in tidal volume (1.44 ± 0.23 ml/min in I/R group vs. 2.41 ± 0.31 ml/min in sham group; P< 0.001), lung compliance (0.27 ± 0.06 ml/cmH2O in I/R group vs. 0.44 ± 0.09 ml/cmH2O in sham group; P< 0.001; 1 cmH2O=0.098 kPa), and oxygen partial pressure (PaO2) levels (64.12 ± 12 mmHg in I/R group vs. 114 ± 8.0 mmHg in sham group; P< 0.001; 1 mmHg = 0.133 kPa). In contrast, these parameters in the BV group (2.27 ± 0.37 ml/min of tidal volume, 0.41 ± 0.10 ml/cmH2O of compliance, and 98.7 ± 9.7 mmHg of PaO2) were significantly higher compared with the I/R group (P = 0.004, P< 0.001, and P< 0.001, respectively). Compared to the I/R group, the contents of superoxide dismutase were significantly higher (47.07 ± 7.91 U/mg protein vs. 33.84 ± 10.15 U/mg protein; P = 0.005) while the wet/dry weight ratio (P < 0.01), methane dicarboxylic aldehyde (1.92 ± 0.25 nmol/mg protein vs. 2.67 ± 0.46 nmol/mg protein; P< 0.001), and adenosine triphosphate contents (297.05 ± 47.45 nmol/mg protein vs. 208.09 ± 29.11 nmol/mg protein; P = 0.005) were markedly lower in BV-treated lungs. Histological analysis revealed that BV alleviated LIRI. Furthermore, the expression of inflammatory cytokines (interleukin-1β, interleukin-6, and tumor necrosis factor-β) was downregulated and the expression of cyclooxygenase-2, inducible nitric oxide synthase, and Jun N-terminal kinase was significantly reduced in BV group (all P< 0.01 compared to I/R group). Finally, the apoptosis index in the BV group was significantly decreased (P < 0.01 compared to I/R group).

conclusionBV protects lung IRI through its antioxidative, anti-inflammatory, and anti-apoptotic effects.

Indexed as

AnimalsAnti-Inflammatory AgentsAntioxidantsApoptosisBiliverdineBlotting, WesternCyclooxygenase 2In Situ Nick-End LabelingInterleukin-1betaInterleukin-6JNK Mitogen-Activated Protein KinasesLungLymphotoxin-alphaNitric Oxide Synthase Type IIRatsRats, Sprague-DawleyAnti-Inflammatory AgentsAntioxidantsBiliverdineCyclooxygenase 2Interleukin-1betaInterleukin-6JNK Mitogen-Activated Protein KinasesLymphotoxin-alphaNitric Oxide Synthase Type IISuperoxide Dismutase

Identifiers

PMID28345551
PMCPMC5381321
OpenAlexW2598328793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.